{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02012153",
      "OrgStudyIdInfo": {
        "OrgStudyId": "MSC-Tx tolerance"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "2013-003221-29",
            "SecondaryIdType": "EudraCT Number"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Mario Negri Institute for Pharmacological Research",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Mesenchymal Stromal Cells in Kidney Transplant Recipients",
      "OfficialTitle": "Autologous Mesenchymal Stromal Cells to Induce Tolerance in Living-donor Kidney Transplant Recipients"
    },
    "StatusModule": {
      "StatusVerifiedDate": "November 2021",
      "OverallStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "December 2013"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2022",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "March 2023",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "November 29, 2013",
      "StudyFirstSubmitQCDate": "December 10, 2013",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "December 16, 2013",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "November 24, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "November 26, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Mario Negri Institute for Pharmacological Research",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "A.O. Ospedale Papa Giovanni XXIII",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The general aim of the present study is to test a cell therapy with autologous ex-vivo expanded mesenchymal stromal cells (MSCs) as a strategy to induce tolerance in living-donor kidney transplant recipients. MSCs will be prepared accordingly to established protocols, starting from bone marrow explants of living-donor kidney transplant recipients obtained 3-4 months before kidney transplant. From these samples, MSCs will be expanded in Good Manufacturing Practice (GMP) approved facilities and used for the present study in patients undergoing kidney transplantation."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Kidney Transplant Rejection"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Mesenchymal stromal cells",
          "Kidney transplantation",
          "Tolerance"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "6",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Mesenchymal Stromal Cells",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "A single intravenous infusion of ex-vivo expanded autologous MSCs will be performed in patients in addition to the living-donor kidney transplantation.\n\n2x10 elevated to sxth power MSCs per kilogram body weight previously isolated from the same recipient will be infused intravenously the day before the kidney transplant procedure.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Mesenchymal Stromal Cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Mesenchymal Stromal Cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Mesenchymal Stromal Cells"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Circulating na√Øve and memory T cell count (CD45RA/CD45RO) (flow cytometry analysis).",
            "PrimaryOutcomeTimeFrame": "Changes from baseline at 6 and 12 months after transplant."
          },
          {
            "PrimaryOutcomeMeasure": "T-cell function by ELISPOT assay in mixed lymphocyte reaction.",
            "PrimaryOutcomeTimeFrame": "Changes from baseline at 6 and 12 months after transplant."
          },
          {
            "PrimaryOutcomeMeasure": "Number of adverse events.",
            "PrimaryOutcomeDescription": "At each visit the overall clinical condition of the patient will be evaluated and any adverse event will be recorded.",
            "PrimaryOutcomeTimeFrame": "Changes from baseline up to 48 months."
          },
          {
            "PrimaryOutcomeMeasure": "Circulating regulatory T cell count.",
            "PrimaryOutcomeTimeFrame": "Changes from baseline at 6 and 12 months after transplant."
          },
          {
            "PrimaryOutcomeMeasure": "Urinary FOXP3 mRNA expression evaluated by real time quantitative PCR.",
            "PrimaryOutcomeTimeFrame": "Changes from baseline at 6 and 12 months after transplant."
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nMale and female patients;\nAged 18 or older;\nLiving-donor (related and unrelated, spouse/husband) kidney transplant recipients;\nNon-Human Leukocyte Antigen (HLA) identical with the donor (one or two haplotype mismatches);\nFirst kidney transplant;\nCapable of understanding the purpose and risk of the study;\nWritten informed consent.\n\nExclusion Criteria:\n\nMSC donor positive for HIV-1, HIV-2, hepatitis B virus (HBV),hepatitis C virus (HCV), syphilis;\nSpecific contraindication to MSC infusion;\nAny clinical relevant condition that might affect study participation and/or study results;\nPregnant women and nursing mothers;\nUnwillingness or inability to follow study protocol in the investigator's opinion.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Norberto Perico, MD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "0039 035 45351",
            "CentralContactEMail": "norberto.perico@marionegri.it"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Giuseppe Remuzzi, MD",
            "OverallOfficialAffiliation": "A.O. Ospedale Papa Giovanni XXIII",
            "OverallOfficialRole": "Study Chair"
          },
          {
            "OverallOfficialName": "Norberto Perico, MD",
            "OverallOfficialAffiliation": "Istituto Di Ricerche Farmacologiche Mario Negri",
            "OverallOfficialRole": "Study Director"
          },
          {
            "OverallOfficialName": "Giovanni Rota, MD",
            "OverallOfficialAffiliation": "A.O. Ospedale Papa Giovanni XXIII",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "Federica Casiraghi",
            "OverallOfficialAffiliation": "Istituto Di Ricerche Farmacologiche Mario Negri",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "Martino Introna, MD",
            "OverallOfficialAffiliation": "Laboratorio G. Lanzani, Bergamo, Italy",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "Alessandro Rambaldi, MD",
            "OverallOfficialAffiliation": "A.O. Ospedale Papa Giovanni XXIII",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "U.O. Nefrologia e Dialisi",
            "LocationStatus": "Recruiting",
            "LocationCity": "Bergamo",
            "LocationZip": "24127",
            "LocationCountry": "Italy",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Piero Ruggenenti, MD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "0039 035 2674037",
                  "LocationContactEMail": "pruggenenti@hpg23.it"
                },
                {
                  "LocationContactName": "Eliana Gotti, MD",
                  "LocationContactRole": "Sub-Investigator"
                }
              ]
            }
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "29963053",
            "ReferenceType": "derived",
            "ReferenceCitation": "Perico N, Casiraghi F, Todeschini M, Cortinovis M, Gotti E, Portalupi V, Mister M, Gaspari F, Villa A, Fiori S, Introna M, Longhi E, Remuzzi G. Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy. Front Immunol. 2018 Jun 14;9:1359. doi: 10.3389/fimmu.2018.01359. eCollection 2018."
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    }
  }
}